Skip to main content

Celcuity Inc 10-Q for FY2026 Q3

Celcuity Inc. (CELC)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Celcuity Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Celcuity launched REVTORPYK after FDA approval for adults with HR+/HER2- ABC without a PIK3CA mutation, but recognized no product revenue through September 30, 2026; its nine-month net loss was $205.0 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$73.34M
compared with a net loss of $43.8M a year earlier
Diluted EPS
-$1.33
compared with -$0.92 a year earlier